Fuzhegn Nizeng Decoction
PreclinicalSmall molecule
Fuzhegn Nizeng Decoction is one of 11 small molecule programs targeting Intraepithelial Neoplasia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Intraepithelial Neoplasia
#DrugCompanyPhaseTrials
1Intron a
Merck & Co.Approved
Aldara
BBausch Health Americas, Inc.
Approved
Fareston
Kyowa Kirin Co., Ltd.Phase 3
Nolvadex
AstraZenecaPhase 3
Gardasil
Merck & Co.Approved
Mitomycin C
GGynecologic Oncology Group
Approved
Aromasin
PfizerPhase 2
Keytruda
Merck & Co.Phase 2
Polyphenon E
LLouisiana State University Health Sciences Center Shreveport
Phase 2
Artesunate Suppositories
SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fuzhegn Nizeng Decoction. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University First Hospital